Kezar Life Sciences (NASDAQ:KZR) Sees Strong Trading Volume – What’s Next?

Kezar Life Sciences, Inc. (NASDAQ:KZR) shares saw unusually-high trading volume on Thursday . Approximately 47,512 shares were traded during trading, a decline of 36% from the previous session’s volume of 74,244 shares.The stock last traded at $7.52 and had previously closed at $8.19.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, October 14th.

Kezar Life Sciences Stock Performance

The firm has a market cap of $52.60 million, a price-to-earnings ratio of -0.53 and a beta of 0.21. The firm’s 50 day moving average is $6.92 and its 200-day moving average is $6.89. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.58 and a current ratio of 9.58.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($2.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.20) by $0.40. Sell-side analysts anticipate that Kezar Life Sciences, Inc. will post -11.95 earnings per share for the current fiscal year.

Institutional Trading of Kezar Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the company. Stonepine Capital Management LLC acquired a new position in Kezar Life Sciences in the 2nd quarter valued at $630,000. BNP Paribas Financial Markets increased its stake in shares of Kezar Life Sciences by 35.4% in the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after purchasing an additional 71,543 shares during the period. Vanguard Group Inc. lifted its position in shares of Kezar Life Sciences by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock worth $2,790,000 after purchasing an additional 30,740 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Kezar Life Sciences by 42.5% during the 1st quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock worth $1,613,000 after purchasing an additional 534,203 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Kezar Life Sciences in the 2nd quarter valued at approximately $63,000. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.